Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes. Issue 9 (14th July 2022)
- Record Type:
- Journal Article
- Title:
- Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes. Issue 9 (14th July 2022)
- Main Title:
- Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes
- Authors:
- Roosa, Colleen A.
Ma, Mingyang
Chhabra, Preeti
Brayman, Kenneth
Griffin, Donald - Abstract:
- Abstract: Type 1 diabetes (T1D) is caused by the autoimmune loss of insulin‐producing beta cells in the pancreas. The only clinical approach to patient management of blood glucose that doesn't require exogenous insulin is pancreas or islet transplantation. Unfortunately, donor islets are scarce and there is substantial islet loss immediately after transplantation due, in part, to the local inflammatory response. The delivery of stem cell‐derived beta cells (e.g., from induced pluripotent stem cells) and dissociated islet cells hold promise as a treatment for T1D; however, these cells typically require re‐aggregation in vitro prior to implantation. Microporous scaffolds have shown high potential to serve as a vehicle for organization, survival, and function of insulin‐producing cells. In this study, the use of microporous annealed particle (MAP) scaffold for delivery of enzymatically dissociated islet cells, a model beta cell source, within the scaffold's interconnected pores is investigated. It is found that MAP‐based cell delivery enables survival and function of dissociated islets cells both in vitro and in an in vivo mouse model of T1D. Abstract : In this manuscript, the delivery of dissociated islets within the pores of microporous annealed particle (MAP) scaffold to treat Type 1 diabetes is reported. It is found that MAP scaffold supports the viability and function (glucose stimulated insulin secretion) of dissociated islet in vitro, as well as maintains normoglycemiaAbstract: Type 1 diabetes (T1D) is caused by the autoimmune loss of insulin‐producing beta cells in the pancreas. The only clinical approach to patient management of blood glucose that doesn't require exogenous insulin is pancreas or islet transplantation. Unfortunately, donor islets are scarce and there is substantial islet loss immediately after transplantation due, in part, to the local inflammatory response. The delivery of stem cell‐derived beta cells (e.g., from induced pluripotent stem cells) and dissociated islet cells hold promise as a treatment for T1D; however, these cells typically require re‐aggregation in vitro prior to implantation. Microporous scaffolds have shown high potential to serve as a vehicle for organization, survival, and function of insulin‐producing cells. In this study, the use of microporous annealed particle (MAP) scaffold for delivery of enzymatically dissociated islet cells, a model beta cell source, within the scaffold's interconnected pores is investigated. It is found that MAP‐based cell delivery enables survival and function of dissociated islets cells both in vitro and in an in vivo mouse model of T1D. Abstract : In this manuscript, the delivery of dissociated islets within the pores of microporous annealed particle (MAP) scaffold to treat Type 1 diabetes is reported. It is found that MAP scaffold supports the viability and function (glucose stimulated insulin secretion) of dissociated islet in vitro, as well as maintains normoglycemia in a streptozotocin‐induced mouse model of diabetes. … (more)
- Is Part Of:
- Advanced therapeutics. Volume 5:Issue 9(2022)
- Journal:
- Advanced therapeutics
- Issue:
- Volume 5:Issue 9(2022)
- Issue Display:
- Volume 5, Issue 9 (2022)
- Year:
- 2022
- Volume:
- 5
- Issue:
- 9
- Issue Sort Value:
- 2022-0005-0009-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-07-14
- Subjects:
- cell delivery -- hydrogel scaffold -- injectable biomaterial -- islet delivery -- type 1 diabetes
Therapeutics -- Periodicals
Pharmaceutical technology -- Periodicals
Pharmacogenetics -- Periodicals
615.5 - Journal URLs:
- https://onlinelibrary.wiley.com/loi/23663987 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/adtp.202200064 ↗
- Languages:
- English
- ISSNs:
- 2366-3987
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0696.935580
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23209.xml